Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research note issued to investors on Tuesday, RTT News reports. They presently have a $48.00 price objective on the stock, down from their prior price objective of $50.00. Wedbush’s price target suggests a potential […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) insider Benjamin T. Dake sold 10,283 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $15.52, for a total value of $159,592.16. Following the transaction, the insider now owns 1,291 shares in the company, valued […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 5,478 shares of the stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $18.00, for a total transaction of $98,604.00. The transaction was disclosed in a legal filing with the Securities & […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) insider Benjamin T. Dake sold 10,283 shares of the stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $16.66, for a total value of $171,314.78. Following the sale, the insider now directly owns 1,291 shares of the company’s […]
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 913,900 shares, a decrease of 5.3% from the April 30th total of 965,000 shares. Based on an average daily trading volume, of 72,700 shares, the short-interest ratio […]